Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper.

7 , 9 , 62 , 63 Stocker et al., 64 in an exploratory analysis of a PETACC 3 study, showed that dose reduction negatively affected relapse-free survival (RFS) [hazard ratio (HR): 0.48, 95% confidence interval (CI), 0.27-0.85; P = 0.01] with a strong trend toward better OS (HR: 0.53, 95% CI, 0.28-1.01; P = 0.052) in patients with BMI ≥30 kg/m 2 and BSA ≥2 m 2 receiving adjuvant chemotherapy for colon cancer. 9 Similarly, the CALGB study 8541 supports the use of full-dose chemotherapy compared with a reduced initial dose due to the improved failure-fr

also in 5,725 other papers